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Abstract Neurogenic bladder is a heterogeneous entity that
may result from a variety of conditions affecting the central or
peripheral nervous systems. Regardless of etiology, the overall
goals of management are primarily twofold. As a neurogenic
bladder may affect the ability to store urine safely and to
empty the bladder efficiently, early management is focused
on optimization of bladder storage function to prevent irre-
versible injury to either the upper or lower urinary tracts. In
older children, this goal is added to the challenge of maximiz-
ing quality of life through achievement of urinary continence
and independence in bladder management that continues into
the transition to adulthood.
In this review,we seek to bring the reader up-to-date regarding
management of the pediatric neurogenic bladder with a focus on
literature published in the past year.We discuss key contributions
related to fetal intervention for myelomeningocele, monitoring
and medical management of the neurogenic bladder and predic-
tion of postoperative outcomes. Put together, these studies high-
light the continued need for further research to improve
evidence-based medical and surgical decision-making strategies
for children affected by neurogenic bladder.
This article is part of the Topical Collection on Pediatric Bladder
Dysfunction
* Earl Y. Cheng
ECheng@luriechildrens.org
1 Division of Urology, Ann and Robert H. Lurie Children’s Hospital of
Chicago, 225 E. Chicago Ave, Box 24, Chicago, IL 60611, USA
2 Department of Urology, Feinberg School of Medicine at
Northwestern University, 303 E. Chicago Ave, Chicago, IL 60611,
USA
Curr Bladder Dysfunct Rep (2016) 11:225–233
DOI 10.1007/s11884-016-0371-6
Keywords Urinary bladder neurogenic . Pediatrics .
Urology . Urinary bladder . Urinary incontinence
Introduction
The normal lower urinary tract allows for both coordinated
low-pressure filling and periodic voluntary bladder emptying.
Given the complexity of its neural control, central or periph-
eral nervous system lesions that affect the parasympathetic,
sympathetic or somatic systems may have varied effects on
the lower urinary tract. Thus, a neurogenic bladder in children
may occur secondary to central nervous system (CNS) lesions
such as cerebral palsy, spinal dysraphisms and spinal cord
injury or secondary to pelvic pathology such as tumors and
anorectal malformations.
The goals in management of the neurogenic bladder are
primarily twofold. As a neurogenic bladder may affect the
ability to store urine safely and to empty the bladder efficient-
ly, early management is focused on optimization of bladder
function to prevent irreversible morphological and functional
injury to either the upper or lower urinary tracts. In older
children, this goal is added to the challenge of maximizing
quality of life through achievement of urinary continence
and independence in bladder management.
In this review, we seek to bring the reader up-to-date re-
garding management of the pediatric neurogenic bladder with
a focus on literature published in the past year. We will discuss
key contributions related to fetal intervention for
myelomeningocele, monitoring and medical management of
the neurogenic bladder and prediction of postoperative out-
comes. Put together, these studies highlight the continued
need for further research to improve evidence-based medical
Myelomeningocele: Fetal Surgery and Urinary Tract
Outcomes
Although an initial decline in incidence of myelodysplasia
was observed following widespread folate supplementation,
the incidence of 3.7 per 10,000 live births in the United States
[1] has stabilized during the past decade [2]. Given its sub-
stantial long-term morbidity and potential to impact neurolog-
ic development, prenatal closure of the open myelo-
meningocele defect has been initiated in specialized centers.
While fetal closure has been associated with improvement in
hydrocephalus and motor function, early reports of its effect
on the urinary tract have been less promising [3–5].
The Management of Myelomeningocele Study (MOMS)
was a randomized prospective clinical trial evaluating prenatal
versus neonatal closure of openmyelomeningocele. Early trial
outcomes included decreased CSF shunt placement rates and
improved mental development and motor function measures
at age 30 months following in utero closure [6]. However, a
subsequent evaluation of urologic outcomes found no differ-
ence in the rates of children meeting criteria for initiation of
clean intermittent catheterization (CIC) by 30 months (38 ver-
sus 51 % of the prenatal and postnatal surgery groups respec-
tively; RR 0.74, 95 % CI 0.48–1.12). Secondary effects in-
cluded less trabeculation in the prenatal surgery cohort and,
after adjustment for gender and lesion level, a decrease in the
presence of bladder diverticulae and open bladder neck during
filling [7•].
In the past year, two additional institutional series eval-
uating urinary tract outcomes following prenatal
myelomeningocele closure were published. In the first se-
ries, only two of 48 infants at a mean age of 5.4 months
had a normal bladder on urodynamics while findings that
may place the upper tracts at increased risk (end fill or
detrusor leak point pressure (EFP or DLPP) of >40 cm/
H20) were present in 56 %. Furthermore, upper tract
changes were present early with hydronephrosis or
vesicoureteral reflux (VUR) observed in 26 % [8]. In a
second series of 58 children followed up to 5 years after
prenatal closure, only 19 % were successfully toilet-trained
[9]. Additional long-term assessment will continue to pro-
vide information regarding the effects of in utero closure
on the urinary tract. In the interim, these findings empha-
size the importance of educating parents that ongoing uro-
logic assessment and management are essential for chil-
dren post prenatal myelomeningocele closure as they re-
main at significant risk for the development of a neuro-
genic bladder.
Radiologic and Urodynamic Assessment
of the Neurogenic Bladder
The current options available to evaluate the neurogenic blad-
der and upper tracts include ultrasonography (US), fluorosco-
py, nuclear medicine studies or urodynamic testing. As was
discussed in a recent review regarding the urologic manage-
ment of spina bifida [10••], there is a current debate regarding
the optimal role and timing of these studies fueled by a desire
to prevent excessive invasive testing and radiation exposure.
This debate is reflected in recent literature that has evaluated
the diagnostic and prognostic value of each test including the
use of nuclear medicine studies versus US in evaluation of the
upper urinary tract, non-invasive methods of bladder wall as-
sessment and urodynamics in children undergoing tethered
cord release (TCR).
Evaluation of Renal Scarring: DMSAVersus US
Regardless of management strategy, the goal to detect early
upper tract changes that may precede deterioration is key to
long-term prevention of renal failure. Prior series of children
with myelodysplasia have demonstrated rates of renal scarring
or functional loss of 10-32 % on DMSA nuclear medicine
scans [11–14]. As a follow-up study, 122 adults with spina
bifida were evaluated with both DMSA and US modalities to
obtain a baseline assessment of renal scarring. A significant
difference in renal scar detection was observed between US
(10 %) and DMSA scans (46 %). Additionally, hypertension
was only correlated with the presence of scarring on DMSA in
this adult population [15•]. Recent literature evaluating the
optimal imaging strategy following a febrile UTI in children
likewise demonstrated that even the most optimized current
model based on US findings has a low predictive value for
either renal parenchymal anomalies or the presence of VUR
[16]. Although the majority of these studies evaluated children
with non-neurogenic bladders, [17] the lack of sensitivity of
US for either VUR or renal scarring is of particular interest in
neurogenic bladder given the need to prevent irreversible renal
damage and the association of VUR with renal cortical loss in
these children [11–14]. These findings require future evalua-
tion but call into question the premise of an evaluation strategy
that is reliant on US changes to precede further testing or
intervention.
Non-invasive Monitoring of Lower Urinary Tract
Function
There is ongoing need for improved methodologies to assess
early alterations in the bladder wall that may portend devel-
opment of poor compliance. Bladder wall hypertrophy with its
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and surgical decision-making strategies for children affected
by neurogenic bladder.
associated morphologic changes may decrease bladder com-
pliance through effects on smooth muscle, connective tissue,
innervation and tissue hypoxia. The ultrasonographic assess-
ment of the bladder wall as a clinically meaningful outcome
requires the ability to reliably assess these changes early when
an intervention may reverse or halt progression toward irre-
versible decompensation [18]. In the largest recent study eval-
uating the utility of bladder wall measurements by US in the
neurogenic bladder, 272 adult patients with SCI were evalu-
ated. Although no threshold wall thickness was predictive of
urodynamic findings, BWTwas significantly increased in in-
dividuals with neurogenic detrusor overactivity associated
with detrusor sphincter dyssynergia (NDO/DSD) or impaired
bladder compliance compared to those without DSD [19]. On
the other hand, in the actively managed pediatric neurogenic
bladder, this predictive capacity of BWTmay be more elusive
as demonstrated by multiple series with mixed results
[20–22]. In particular, a recent study of 53 closely managed
children with spina bifida found that BWTwas not predictive
of unfavorable urodynamic parameters even when measured
at specified bladder volumes [23•]. To improve the predictive
capability of non-invasive studies of the lower urinary tract,
our center is currently evaluating alternative technologies in-
cluding bladder elastography as a potential solution to the
ongoing need for a non-invasive evaluation strategy for these
children.
Predictive Urologic Changes in Tethered Cord
Release
Urologic findings are often the first clinical sign in the up to
one third of individuals who develop symptomatic tethering
on long-term follow-up after postnatal myelomeningocele clo-
sure [24]. Two series were published in reference to sec-
ondary tethering and urologic outcomes of children in the
past year. In a series of 23 children with secondary teth-
ered cord, TCR significantly improved bladder compli-
ance, DLPP and EFP. Urologic symptoms were improved
in 62 % with all previously incontinent children reporting
resolved or improved continence postoperatively [25].
These findings added to a growing body of literature eval-
uating clinical outcomes following primary TCR in occult
spinal dysraphism. In a recent series from our institution,
although asymptomatic children with cutaneous lesions
had excellent continence rates post-TCR, no specific
urodynamic parameters were associated with urologic out-
comes [26]. Similarly, in a second series of 40 children
although significant improvement in both continence and
UTI rates were observed following secondary TCR, pre-
operative neurologic symptoms prompting TCR were not a
predictor of urologic outcomes [27]. Taken together, an
improvement in bladder dynamics or symptoms may be
observed following either primary or secondary TCR.
However, as the current ability to predict such changes
is limited, urologic follow-up with a postoperative
urodynamic evaluation may be warranted following these
procedures.
Management of the Neurogenic Bladder
Prior to the widespread utilization of CIC for the management
of neurogenic bladder, renal failure and urosepsis were com-
mon causes of long-term morbidity and mortality. Recent
baseline data of 2172 participants in the National Spina
Bifida Registry provides a window into current management.
In the specialized centers participating, 74 % of participants
with myelomeningocele and bladder impairment utilized CIC
[28]. Fortunately, in this era of CIC incorporation into prac-
tice, long-term success has been achieved in preventing VUR
and hydronephrosis, decreasing augmentation cystoplasty
(AC) rates and reducing postoperative mortality secondary
to renal failure [29–31]. The challenge remains, however, to
identify children whowould benefit from initiation of CIC and
the optimal timing for each medical or surgical intervention
currently available.
Medical Management
In a stepwise process of neurogenic bladder management,
initial efforts at maintaining a compliant storage reservoir
and treatment of urinary continence are focused on improved
bladder drainage through catheterization and the addition of
medications in an individualized manner. If the desired result
is not achieved through anticholinergic therapy, another com-
bination of medications, endoscopic management or
neuromodulation may be utilized prior to surgical reconstruc-
tive procedures. Recent studies have focused on medical man-
agement alternatives and the efficacy of intravesical Botox for
these children.
Anticholinergics and Pharmacologic Therapy
Anticholinergic therapy has been demonstrated to have both
short- and long-term effects on the bladder. A longitudinal
study of 121 children with neurogenic bladder treated for a
median duration of 19 months found that oral oxybutynin had
sustained effects on both continence and bladder compliance.
Of the 51 children with a pretreatment EFP of >40 cm/H20,
mean EFP decreased to and remained <40 cm/H20 in 63 %
throughout treatment. Oxybutynin was well tolerated with on-
ly six discontinuations due to AEs [32].
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As an alternative route of administration, intravesical
oxybutynin has also been evaluated for its potential to de-
crease the side effects of anticholinergic therapy by reducing
first pass metabolism in the liver while maintaining high sys-
temic efficacy and bioavailability [33–36]. A recent publica-
tion reported 15-year mean follow-up following transition
from oral to intravesical oxybutynin for pediatric NGB in
ten children with DSD. Ongoing suppression of detrusor over-
activity, maintenance of long-term effects on bladder compli-
ance (30 % at onset versus 90 % at last follow-up had an EFP
<40 cm/H20) and increased bladder capacity (from 5th to 25–
50th percentile for age) was observed. Intravesical oxybutynin
was well-tolerated; no side effects were reported [37••].
Finally, medication alternatives to anticholinergic therapy
are being evaluated. A recent study highlighted the potential
for further targeting of the adrenergic pathway by finding an
association between children whose LUTS failed to respond
to anticholinergics and genetic polymorphisms in the adrener-
gic rather than cholinergic pathway [38]. An example of an
alternative agent that targets adrenergic transmission is
mirabegron, a β3 agonist demonstrated to have efficacy in
adults with NDO due to SCI with significant decreases in
EFP, frequency of evacuation and incontinence episodes
[39]. Although anticholinergic therapy is currently the main-
stay of medical management for pediatric NGB, further stud-
ies may provide additional options for medical management,
including the potential for targeted pharmacologic manipula-
tion of the adrenergic pathway in children with NDO.
Intravesical Botulinum Toxin A
Botulinum toxin A was FDA approved in adults for
intravesical injection in the treatment of urinary incontinence
due to NDO. Prospective assessments in children with NGB
have likewise demonstrated significant improvement in con-
tinence, bladder capacity and compliance following Botox
injection [40, 41]. In addition, a decrease in fibrosis after mul-
tiple injections has been described that may correspond to the
potential for inhibition of detrimental remodeling in certain
bladders [42].
Two retrospective series recently explored outcomes in the
treatment of pediatric NGB and optimization of patient selec-
tion for intravesical Botox therapy. Khan et al. reviewed the
experience at a single center of children with NDO who were
either anticholinergic refractory or intolerant [43•]. Following
injection of 300U into the detrusor, 54 % of children reported
improved continence. A corresponding increase in mean
cystometric capacity and a decrease in EFP and frequency of
uninhibited detrusor contractions were observed. Mean dura-
tion of clinical effectiveness was 4.6 months (range 0–18). Of
note, continence rates appeared to be highest in the subset of
children with anticholinergic intolerance (75 %) versus those
refractory to medical management (50 %) following Botox
injection. Although interpretation remains inconclusive as
the number within the cohort intolerant of anticholinergic ther-
apy was small, it was hypothesized that these children may
represent a subset less likely to have a fibrotic bladder [43•].
This observation aligns with publications by Tiryaki [44],
Kim [45], and Kask et al. [46] which all found that severely
impaired bladder compliance, particularly in the presence of a
lack of detrusor activity, portends the poorest prognosis for
response to intravesical botox injections in children with
NGB. In these series, children with NDO and mild to moder-
ate changes in compliance had a better response both in terms
of continence and bladder dynamics following intravesical
botox injection as compared to those with more severe com-
pliance changes.
Regardless of the efficacy of a single intravesical
Botox treatment for these children, however, a follow-
up question recently addressed was its utility as a
chronic management strategy. In 22 children with
NDO who underwent a total of 62 intravesical Botox
injections over a 10-year period, the median response
time was 7 months (range 0–25) with a stable response
observed up to a 7th injection [47••]. This aligns with a
former series of eight children with NGB whose pre and
postoperative urodynamics demonstrated a mean EFP
decrease to <40 cm/H20 and a consistent increase in
bladder capacity after each of three repeated injections
[48]. Although not currently FDA approved for treat-
ment of NDO in children, Botox is a promising early
alternative to augmentation, particularly for those indi-
viduals who are intolerant of anticholinergic therapy.
Further studies are anticipated to continue to elucidate
the optimal candidates, timing and utility of early treat-
ment with Botox in children with NDO.
Surgical Reconstruction
When medical and intravesical options fail to provide satis-
factory results, surgical reconstruction may be required to
maintain low intravesical storage pressure and achieve treat-
ment goals for urinary continence. Current options for surgical
management include incontinent diversion for those who are
not candidates for CIC or individualized combinations of aug-
mentation cystoplasty (AC), a bladder outlet procedure such
as bladder neck reconstruction (BNR), sling, artificial urethral
sphincter or bladder neck closure (BNC) and creation of a
catheterizable channel [10••]. In the past year, literature con-
tributions included analyses of enterocystoplasty (EC) out-
comes, the selection of children for bladder neck reconstruc-
tion without concurrent bladder augmentation and the
expanding role of robotics in reconstructive surgery.
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Outcomes Following Augmentation Cystoplasty
The most common tissue sources currently utilized for AC are
autologous ileum or colon. Although typically effective in
increasing bladder capacity and compliance, an EC is associ-
ated with both short- and long-term morbidity and requires
lifelong urologic management. Two recent analyses of the
American College of Surgeons’ National Surgical Quality
Database (NSQIP) reported an approximately 30 % (23–
33 %) 30-day overall event rate in children who underwent
EC with or without appendicovesicostomy. The most com-
mon complications included urinary tract infections (9.6–
10.7 %), wound complications (7.4–8.7 %), blood transfu-
sions (6–6.1 %) and sepsis (2.8–3.5 %). Median length of stay
was 8 days in both analyses with 30-day reoperative rates of
up to 10 % and readmission rates of 13 % [49•, 50•]. In a
separate study, when comorbidities were analyzed for contri-
bution to perioperative outcomes in urologic bowel proce-
dures, a BMI ≥95th percentile was found in 21 % of these
children and was associated with both a fourfold increase in
adjusted odds of overall wound complications [51] and an
increased 30-day overall event rate [52].
In addition to short-term outcomes, 10-year cumulative
complication incidence was calculated from the Pediatric
Health Information System database in evaluation of 2831
augmentation cystoplasties. Causes of long-term morbidity
included bladder rupture (2.9–6.4 %), small bowel obstruction
(5.2–10.3 %), bladder stones (13.3–36 %) and pyelonephritis
(16.1–37.1 %). Secondary surgery estimates included a 13.3–
35.1 % rate of cystolitholapaxy and re-augmentation in 5.2–
13.4 % [53]. In analysis of risk factors, an increased risk of
bladder rupture and stone development was associated with
bladder neck procedures and stoma creation at the time of
augmentation [53].
Taken together, outcome studies such as these highlight
both the importance of life-long urologic care following EC
and the need for alternative management strategies. To date,
bioengineered tissue alternatives have provided less than de-
sirable human applicability with survival of large grafts limit-
ed in part by a lack of early vascularization leading to early
functional loss and fibrosis [54, 55]. However, the significant
morbidity associated with the use of autologous bowel for AC
should continue to provide impetus for ongoing research to
create viable tissue alternatives for these children.
Outcomes of Bladder Neck Procedures
Without Augmentation Cystoplasty
In the National Spina Bifida Patient Registry database,
less than one third of children with spina bifida at their
baseline registry evaluation were continent of either
urine or stool [28]. For children with minimal outlet
resistance who have not achieved the desired continence
result via medical management, the surgical solution
most often offered historically was a concurrent bladder
neck reconstructive procedure, catheterizable channel
and augmentation cystoplasty. In an attempt to address
the morbidity of EC, multiple series have recently
questioned the necessity of bladder augmentation in all
cases [56].
In three recent series with 2 to 9 years of follow-up,
children who underwent isolated bladder neck procedures
proceeded to augment between 12 and 45 % of the time
[57••, 58•, 59•]. Unfortunately, regardless of methodology
utilized for urodynamic testing, no definitive preoperative
urodynamic parameters were identified that could have
predicted the response of each bladder to increased outlet
resistance and the need for subsequent bladder neck or
augmentation procedures. In the largest series, 18 % of
109 children who underwent a bladder outlet procedure
without augmentation followed for a mean of 4.9 years
h a d p r o c e e d e d t o AC . A l t h ou g h upp e r t r a c t
hydronephrosis or VUR resolved in all children in this
series following AC, most concerning was the presence
of new or increased renal scarring observed in 21 % of
children evaluated both before and after an isolated blad-
der outlet procedure. Furthermore, the authors reported an
estimated 10-year cumulative incidence of AC in 30 %,
with over 50 % having developed upper tract changes and
20 % diagnosed with chronic kidney disease. Although
significantly associated with the incidence of new or in-
creased postoperative renal scarring, preoperative bladder
compliance did not correlate with long-term success over-
all [57••]. Putting these series together, although there are
bladders with myogenic failure and adequate compliance
that may maintain low intravesical pressure following an
isolated bladder neck procedure, the ability to preopera-
tively select optimal candidates for BNR without augmen-
tation remains elusive.
Robotic Approaches to Reconstructive Procedures
Surgical options continue to evolve with the application
of a minimally invasive approach to an increasing num-
ber of reconstructive procedures. In the past year, sev-
eral series have reported the feasibility of a robotic ap-
proach for AC, bladder neck reconstruction (BNR) and
appendicovesicostomy. In a retrospective comparison of
open (n = 13) versus robotic (15) ileocystoplasties with
or without concomitant procedures, operative time was
significantly longer (623 versus 287 min) while median
length of stay was decreased (6 versus 8 days) in ro-
botic as compared to open cohorts. Postoperative in-
c rease in b ladder capac i ty, na rco t i c use and
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complication rates did not differ between the two ap-
proaches [60]. Similarly, feasibility was demonstrated
of an entirely intracorporeal robotic EC with or without
creation of catheterizable channels in a recent multi-
institutional series of 22 adults [61]. Specific to the
catheterizable channel, a single center experience of 39
robotic and 28 open appendicovesicostomies reported no
difference in acute complication (26 and 29 %, respec-
tively) or reoperation (29 versus 33 %) rates at a mean
follow-up of 2.8 ± 2.5 years. However, the robotic series
had higher rates of Clavien grade 2–3 complications
including three early reoperations due to early bowel
obstruction with internal hernia in the robotic cohort
addressed by an altered technique with fixation of the
channel and bladder to the abdominal wall [62]. Series
such as these are needed to continue to define the long-
term outcomes of robotic procedures with ongoing pro-
cedural optimization.
Robotic outcomes of bladder neck reconstruction
have also recently been published. In one series, 38
robotic assisted Leadbetter-Mitchell type BNR and con-
tinent catheterizable channels without AC were per-
formed. After a mean follow-up of 21 months, 82 %
of individuals were dry with CIC which compares fa-
vorably with the 50–85 % continence rates published in
the open literature [63]. In a second series, outcomes
were compared between 19 robotic and 26 open bladder
neck reconstructions. Operative time was significantly
longer in the robotic cohort (8.2 versus 4.5 h) but no
difference was observed in length of stay (median 4 days
in each cohort) or acute complication rates (16 and
12 %, respectively). With a mean followup of 2.3 ver-
sus 3.2 years in the robotic versus open cohorts, there
was no difference in rates of subsequent incontinence
procedures performed in 42 and 56 % of children re-
spectively [64].
As robotic procedures become increasingly common,
recent studies have evaluated means to optimize perioper-
ative care. A recent assessment of regional anesthesia op-
tions following robotic assisted procedures including
transversus abdominal plane (TAP) and caudal blocks ver-
sus no regional block addressed these questions. A signif-
icant reduction in intraoperative opioid use and need for
antiemetics was seen in children undergoing upper or low-
er tract urologic robotic surgery with a caudal block as
compared to TAP or no regional anesthesia [65].
However, there was no significant difference in postoper-
ative opioid use, maximum pain scores within 24 h post-
operatively or length of hospital stay [65]. As surgical
management options continue to evolve, ongoing optimi-
zation of surgical planning and perioperative management
continues to be needed to refine techniques and outcomes
for children with neurogenic bladder.
Achieving Long-Term Goals: Quality of Life
Assessment and Transition of Care
To evaluate in a systematic way whether the goals of individ-
uals with neurogenic bladder are being met, several quality of
life assessment tools have recently been evaluated including
QUALAS-A [66] and QUALAS-C [67••] designed for adults
and children with spina bifida as well as adolescent specific
bowel [68] and bladder [69] functional measurement instru-
ments. Although a complex relationship exists, qualitative in-
terviews of youth and parents published in the past year reit-
erated the effect of continence on quality of life through great-
er independence and opportunities for social participation re-
ported in children with minimal versus higher volume incon-
tinence [70]. Development of assessment, educational tools
[71] and options for bladder emptying [72] continue to refine
our understanding to better address the needs of children with
neurogenic bladder through facilitation of independence in
bowel and bladder management.
Children with neurogenic bladder represent one of the larg-
est pediatric populations in need of complex ongoing urologic
management as they transition to adult care. Several studies
that recently evaluated both youth with neurogenic baldder
and their providers have emphasized the need for specialized
treatment availability. In a survey of urologists, the majority
(81 %) recommended that a urologist with training in
adolescent/transitional care and experience in performance
of genitourinary reconstructive procedures is ideally suited
for the care of the mature patient with a complex genitourinary
history [73]. Individuals who had completed this transition of
urologic care were in agreement with the benefits of special-
ized management with 95 % considering their visit to a tran-
sitional care clinic beneficial [74]. Thoughtful planning in this
process including assistance in navigation of an adult
healthcare program and coordination with specialists who
have expertise in this area will help to promote long-term
genitourinary health for individuals with neurogenic bladder.
Conclusion
The goals in management of the pediatric neurogenic
bladder include preservation of the upper and lower
urinary tracts and optimization of quality of life
throughout childhood and in the transition to adulthood.
As highlighted in this review of literature published in
the past year, the techniques of assessment, medical
and surgical management continue to evolve. Ongoing
research to improve understanding of outcome determi-
nants and optimal choice of candidates for each man-
agement strategy continues to be needed to minimize
the significant current impact of the pediatric neurogen-
ic bladder.
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